AJP - Regu Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 287: R342-R348, 2004. First published May 6, 2004; doi:10.1152/ajpregu.00156.2004
0363-6119/04 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
287/2/R342    most recent
00156.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Budzyn, K.
Right arrow Articles by Sobey, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Budzyn, K.
Right arrow Articles by Sobey, C. G.

NEUROHUMORAL CONTROL OF CARDIOVASCULAR FUNCTION

Chronic mevastatin modulates receptor-dependent vascular contraction in eNOS-deficient mice

Klaudia Budzyn, Philip D. Marley, and Christopher G. Sobey

Department of Pharmacology, The University of Melbourne, Parkville, Victoria 3010, Australia

Submitted 10 March 2004 ; accepted in final form 22 April 2004

We tested the hypothesis that endothelial nitric oxide (NO) synthase (eNOS)-derived NO modulates rho-kinase-mediated vascular contraction. Because 3-hydroxy-3-methylglutaryl (HMG)-CoA-reductase inhibition can both upregulate eNOS expression and inhibit rhoA/rho-kinase function, a second hypothesis tested was that statin treatment modulates rho-kinase-mediated contraction and that this can occur independently of eNOS. Contractile responses to the receptor-dependent agonists serotonin and phenylephrine but not to the receptor-independent agent KCl were greater in aortic rings from eNOS-null (eNOS–/–) vs. wild-type (eNOS+/+) mice. Similarly enhanced responses were seen in eNOS+/+ rings after acute NOS inhibition. The rho-kinase inhibitor Y-27632 abolished or profoundly attenuated responses to receptor agonists in both eNOS+/+ and eNOS–/– rings, but responses in eNOS+/+ were more sensitive to Y-27632. Mevastatin treatment (20 mg/kg sc per day, 14 days) reduced responses to serotonin and phenylephrine in female mice of both strains. KCl-induced contractions were slightly smaller in eNOS+/+-derived aortic rings only. Levels of plasma cholesterol, and aortic expression of rhoA and rho-kinase, did not differ between groups. Thus eNOS-derived NO suppresses rhoA/rho-kinase-mediated vascular contraction. Moreover, a similar suppressive effect on rho-kinase-mediated vasoconstriction by statin therapy occurs independently of effects on eNOS or plasma cholesterol.

endothelium; vasoconstriction; statins



Address for reprint requests and other correspondence: C. G. Sobey, Dept. of Pharmacology, The Univ. of Melbourne, Grattan St., Parkville, Victoria 3010, Australia (E-mail: cgsobey{at}unimelb.edu.au).




This article has been cited by other articles:


Home page
CirculationHome page
M. F. Kircher, J. Grimm, F. K. Swirski, P. Libby, R. E. Gerszten, J. R. Allport, and R. Weissleder
Noninvasive In Vivo Imaging of Monocyte Trafficking to Atherosclerotic Lesions
Circulation, January 22, 2008; 117(3): 388 - 395.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
S. Chrissobolis and C. G. Sobey
Recent Evidence for an Involvement of Rho-Kinase in Cerebral Vascular Disease
Stroke, August 1, 2006; 37(8): 2174 - 2180.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Budzyn, P. D. Marley, and C. G. Sobey
Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2004 by the American Physiological Society.